Bioventus (BVS) Cash from Operations Growth (1y) (2021 - 2026)
Analysis
Bioventus (BVS) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | 21.54% |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 48.31% |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 64.80% |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 13.50% |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 14.62% |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 124.64% |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | 0.99% |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | -11.16% |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | -12.60% |
| 10 | Bioventus | 923.70 Mn | 894.24 Mn | 105.67 Mn | -23.38% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 27, 2026 | -23.38% |
| Mar 28, 2026 | 146.22% |
| Dec 31, 2025 | 96.50% |
| Sep 27, 2025 | 191.76% |
| Jun 28, 2025 | 71.07% |
| Mar 29, 2025 | -221.92% |
| Dec 31, 2024 | 86.25% |
| Sep 28, 2024 | 224.06% |
| Jun 29, 2024 | 40.45% |
| Mar 30, 2024 | -228.89% |
| Dec 31, 2023 | 97.83% |
| Sep 30, 2023 | -1,086.16% |
| Jul 1, 2023 | 267.30% |
| Apr 1, 2023 | 122.17% |
| Dec 31, 2022 | -60.02% |
| Oct 1, 2022 | -106.62% |
| Jul 2, 2022 | -83.04% |
| Apr 2, 2022 | -16.50% |
| Dec 31, 2021 | -48.45% |
| Oct 2, 2021 | -50.16% |